AEON Biopharma (NASDAQ:AEON) Shares Down 2.5% – What’s Next?

AEON Biopharma, Inc. (NASDAQ:AEON)’s stock price dropped 2.5% during mid-day trading on Friday . The stock traded as low as $1.14 and last traded at $1.16. Approximately 92,931 shares changed hands during trading, a decline of 67% from the average daily volume of 278,212 shares. The stock had previously closed at $1.19.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the stock. Zacks Research raised shares of AEON Biopharma to a “hold” rating in a report on Tuesday, November 18th. Aegis reissued a “buy” rating on shares of AEON Biopharma in a report on Wednesday, October 8th. Finally, HC Wainwright raised shares of AEON Biopharma to a “strong-buy” rating in a research note on Friday, November 14th. One analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, AEON Biopharma presently has a consensus rating of “Buy”.

AEON Biopharma Stock Performance

The firm’s 50 day moving average is $1.01 and its 200-day moving average is $0.90. The company has a market cap of $13.73 million, a PE ratio of 6.44 and a beta of 0.72.

About AEON Biopharma

AEON Biopharma, Inc, formerly Allied Energy Corp., is a clinical‐stage biopharmaceutical company focused on developing and commercializing treatments for rare and orphan diseases. The company applies enzyme replacement and gene therapy platforms to address unmet medical needs in central nervous system and metabolic disorders. Its lead program, AES-103, is being developed as an enzyme replacement therapy for Crigler-Najjar syndrome, a hereditary condition characterized by high levels of unconjugated bilirubin.

Beyond AES-103, AEON Biopharma is advancing AES-201 for X-linked adrenoleukodystrophy (X-ALD), a progressive neurological disorder, and AES-104 for post–COVID-19 conditions, commonly referred to as “long COVID.” These programs are in preclinical or early clinical stages, with ongoing efforts to optimize delivery, evaluate safety profiles and establish proof of concept.